Business Information
The group's principal activities are to acquire, develop and commercialize novel pharmaceutical products for the treatment of life-threatening diseases including diabetes and cancer. It has two product candidates, krx-101 and krx-0401 in late-stage clinical development. Krx-101 (sulodexide) is a novel oral heparinoid compound for the treatment of diabetic nephropathy, a kidney disease caused by diabetes. Krx-0401 (perifosine) is the prototype of a new group of anti-cancer drugs. Additionally, the group is developing three clinical stage oncology compounds namely: krx-0401, krx-0402 and krx-0403. It also has an active in-licensing and acquisition program designed to identify and acquire clinical-stage drug candidates. On 06-Feb-2004, the group acquired access oncology inc.
|
|
Name |
Title
|
Email
|
| Michael Weiss | Chmn., CEO | N/A | | Beth Levine | Sr. VP, General Counsel, Chief Compliance Officer, Corp. Sec. | N/A | | Mark Stier | VP, Chief Accounting Officer | N/A | | Craig Henderson | Dir., Pres. | N/A | | Eric Rose | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 534 | (73,764) | | 2005 | 574 | (26,895) | | 2004 | 809 | (32,943)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
